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Summary.-The survival of epidermal cells in vivo has been used to assess potential
radiosensitizers. Mouse skin was made acutely hypoxic for the irradiations, to give
radioprotection by a factor of2-7-3-0. Several concentrations of each drug were used
to determine whether any of them were more effective sensitizers than misonidazole.
The SER at each concentration was determined from radlobiological dose-response
curves. The blood concentration and toxicity ofthe compounds were also determined.
The sensitizing efficiency, assessed in several ways, indicated that only Ro 03-8799
gave significantly greater sensitization than misonidazole, and then only when asses-
sed by comparing the compounds on the basis of equimolar blood concentrations.
Ifthe comparison ofefficiency was made in terms of LDso the ranking order changed.
The need for a more clinically relevant test of peripheral neurotoxicity is stressed.
SINCE THE FIRST DEMONSTRATION that
nitroimidazoles can be effective radio-
sensitizers of hypoxic cells in vitro and in
vivo (Foster & Willson, 1973; Begg et al.,
1974; Asquithetal., 1974; Denekamp etal.,
1974) 3 drugs have undergone a battery
ofinvestigations and are now being tested
clinically. Misonidazole (MISO), a 2-
nitroimidazole, and Ro 05-9963, the des-
methyl metabolite, are more effective
sensitizers than the 5-nitroimidazole,
metronidazole, but their clinical use is
limited by neurotoxicity. Many other
structural modifications of the nitro-
imidazoles have now been tested in vitro
(see e.g. Adams et al., 1978; Brady, 1980)
where a good correlation has been de-
monstrated between the electron-affinity
of a compound and its efficiency as a
radiosensitizer (Adams et al., 1979a;
Wardman, 1977). A group of basic 2-
nitroimidazoles have been identified which
are 10 times more efficient than MISO,
even though they should only be 3 times
more effective on the basis of increased
electron affinity (Smithen et at., 1980).
Far fewer sensitizers have been tested
in vivo (Adams et al., 1978; Brady, 1980).
This paper presents data on 6 potential
sensitizers, using MISO as the reference
compound. Some physico-chemical char-
acteristics of the compounds are sum-
marized in Table I. More chemical data,
and invitroradiobiological studies on some
of these compounds, are included in the
publications byAdams etal. (1976, 1979a),
Smithen et al. (1980) and Watts et al.
(1980). The compounds have been tested
using survival of mouse epidermal cells
made artificially hypoxic during irradia-
tion, as described by Denekamp et at.
(1974).
MATERIALS AND METHODS
Albino mice of the WHT inbred strain
were used in all experiments. Two sets of
experiments are included; in the first, male
and female mice aged 3-6 months were used
from a conventional barrier-maintained
colony. In the second series 2-3-month-old
females were used from the SPF colony
(designated WHT/Gy f BSVS) derived by
caesarian section from the original WHT/GyJ. DENEKAMP ET AL.
TABLE I.-Physico-chemical characteristics of the compounds
Compound
Misonidazole
Ro 05-9963
Structure
R-X
Rl-OCH3
Rl-OH
Mlol.
wt
201 2
187 2
Ro 03-8799 R1-N O 290-8
Ro 03-8800 Rl-N ° 292-7
Ro 12-5272 R2-OCH3 219-2
Ro 11-5481 R3-OCH3 234 3
Nimorazole R4-N KI 226*2
One-electron
reduction
potential
E71/mV
- 389
- 389
- 346
-380
-368
-457
-457
Partition
coefficient
octane:water
0 43
0f11
8 50
0 37
0 05
1 40
Distribution
coefficient
pKa at pH 7.4
0 43
- 0-11
8-71
6-15
0-41
0-35
- 0 05
4.99 1*40
CH2CH(OHKCH2-X
N
= N02
CH2-CH2SO2CH-X
N
= N02
CH2CH(OH)CH2-X
R3=6>+SO2CH3
CH2CH2-X
N
= NO-.j
The Ro compounds were supplied by Roche Products Ltd, Welwyn Garden City.
We are indebted to Dr M. Montavon, Hoffman-La Roche, Basle, for Ro 12-5272 and Ro 11-5481.
Nimorazole was supplied by Montedison Ltd, Barnet.
Data from Adams et al. (1976, 1979a) and Smithen et al. (1980).
mice.
' he sex and status of the mice are
indicatjd in the figure legends.
The details of irradiation and scoring
techniques for measuring in vivo survival
ofepidermal cells were adapted from Withers
(1967) and have been described previously
by Denekamp et al. (1974). Briefly, a 30mm
diameter area of skin on the rear dorsum of
the mice was plucked 24 h before irradiation.
The animals were irradiated with 1MeV
electrons under pentobarbitone anaesthesia.
Initially 5 small areas 2-9 mm in diameter
were defined using lead shields. A dose of
30 Gy was administered to air-breathing
mice in order to isolate the test areas from
each other and prevent migration of cells
from the surrounding epidermis. The lead
shields were then removed and the test
dose was administered to mice breathing 02,
or to mice breathing N2 for 35 sec before and
during the irradiation. The test dose was
administered within the last 5 sec of gassing.
All N2-breathing mice were rescued immedi-
ately after irradiation by a rapid change to
02 (Denekamp & Michael, 1972; Denekamp
et al., 1974). Dosimetry was performed with
lithium fluoride discs. The irradiated areas
desquamated by 12-15 days, and if one or
more cells survived in a test area it gave rise
to macroscopically visible "clones" (Withers,
1967). These were assessed 5 times between
Days 14 and 21 after irradiation.
All compounds to be tested were made up
as fresh solutions in sterile saline on the morn-
ing of each experiment. All solutions were
made so that 1 ml would be administered
i.p. to a 30 g mouse, and appropriate volumes
were given according to body wt. All the
compounds used were readily soluble, except
Ro 12-5272, which was prepared as a sus-
pension in 0.25% tragacanth gum and0.005%
Tween-80 in saline, using an ultrasonic
bath to facilitate solvation. Even so, it was
found to be virtually impossible to suspend
the 12 mg/ml needed to give 0-4 mg/g body
wt without sedimentation.
The pharmacokinetics of each compound
were previously determined by Dr T. Marten
using MF1 mice maintained at Roche Pro-
ducts Laboratories at Welwyn Garden City
Solubility
limit in
saline at
220C
(mg/ml)
30
200
> 180
200
3-5
>200
>17
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(personal communication). Based on those
results, the first set of experiments was per-
formed using an interval between drug
administration and irradiation corresponding
to 5 min after the peak drug concentration
in the blood of MF1 mice (i.e. at 10-20 min).
Inthe second series ofexperiments aninterval
bf 10-15 min was used, regardless ofthe time
of peak blood concentration. The pharmaco-
kinetics and toxicology of the compounds
were subsequently determined in the same
SPF female WHT mice used for the radio-
biology. The drug levels were measured on
blood samples from 3 or 4 mice at each point,
using high-performance liquid chromato-
graphy (HPLCj.
RESULTS
Radiobiological data
Figs 1 & 2 show representative sets of
skin-clone data from conventional mice
and SPF mice. In each case, the skin of
mice irradiated breathing N2 is 2-7-
3-0 times more radioresistant than in those
breathing 02 (i.e. *OER=2.7-3.0). The
radiation dose-response curves are steep;
an increase in dose by 20-25% often
reduces the epidermal islands regrowing
from 100 to 0%. The radiation dose range
for the oxic and hypoxic response is similar
for male and female mice, and for con-
ventional and SPF mice (cf. Figs 1 & 2).
Mice irradiated in N2 show an increased
radiosensitivity after administration of a
sensitizing drug, as evidenced by a shift of
the dose-response curve towards the 02
curve. The extent ofthis shift is a measure
of the degree of radiosensitization and is
quantified in terms of the sensitizer en-
hancement ratio (SER).t Fixed drug
doses of 0.1 and 0 4 mg/g were used for
each compound so that a direct compari-
son was possible at equal doses (Figs 1 &
2). A drug dose of about half the LD50
was also used.
For some compounds, lower doses,
extending down to 0-01 mg/g, were also
tested. The SERs have been calculated
from each set of data and are summarized
in Table II.
All the 2-nitroimidazoles tested gave
similarly high SERs at equal doses, none
being better than MISO. The 5-nitro-
imidazole nimorazole was considerably less
effective. The insertion of a sulphonyl
group into the N-I side chain of MISO
(Ro 12-5272) did not markedly depress
the compound's effectiveness, whereas
the substitution of a sulphonyl group for
the nitro group (Ro 11-5481) eliminated
its sensitizing ability (Figs 1 & 2).
30 40
RADIATION DOSE (Gy)
FIG. 1.-The percentage of "clones" regrow-
ing as a function of radiation dose for mice
irradiated in 02, N2 or N2 in the presence of
various radiosensitizing compounds ad-
ministered i.p. at a dose of 04 mg/g body
wt. Top, female mice; bottom, male mice
from the conventional WHT/Gy colony.
Most of the compounds show a significant
sensitizing effect but none ofthem are more
effective than misonidazole. The lines are
best fits by eye. For details of compounds
see Table I.
* OER= =~~~~~~radiation dose inN2togvsaelelfsuia. OER=oxygen enhancement ratio=radiation dose in 02 to give same level of survival.
t SER =sensitizer enhancement ratio =radiation dose without drug in N. to give same level of survival. radiation dose with drug in N2
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FIG. 2. Percentage of clones regrowing as a
function of radiation dose for SPF female
WHT/Gy mice irradiated in 02, or in N2
with 01 mg/g of various radiosensitizers.
Significant sensitization is seen with this
low dose.
Pharmacology data
Some pharmacological data for the
WHT mice (i.e. the strain used for the
radiobiological studies) are indicated in
Table II. The compounds were given
i.p. in a volume of 1-1-5 ml (according to
mouse weight) and blood samples were
obtained by decapitation under ether
anaesthesia, or from the thoracic cavity
after neck luxation without anaesthetic.
Several different drug levels were studied
to match the doses used in the radio-
biological experiments. A wide scatter
in the individual values was seen with
several of the compounds.
Fig. 3 shows the drug concentrations in
blood vs administered dose on a log-log
plot. There is reasonably close propor-
tionality between blood concentration
and dose for all the drugs. Ro 03-8800
gives 5-fold blood concentrations over the
closely related but rather more basic
Ro 03-8799 at all dose levels, probably
because of rapid metabolism of the latter
as it passes through the liver.
The toxicity of these compounds was
tested using 6-8 mice per dose group
and assessing survival 7 days after graded
drug doses. From such dose-response
curves the LD10, LD50 and LDgo have
been estimated, as indicated in Table II.
All the compounds made the mice drowsy
within a short time ofadministration, and
most deaths occurred within 2 days. No
further deaths occurred after 7 days.
The lethality data were fitted by logit
analysis to obtain the quoted values. The
steepness of the dose-effect curves is
reflected in the narrow range from LD10
to LDso.
DISCUSSION
The 7 compounds tested were all
closely related imidazoles, mostly with
substitutions at N-1 of the imidazole
ring. The mol. wts ofthe compounds varied
by a factor of 1P6 (Table I). The electron-
affinities, measured as one-electron reduc-
tion potentials, fell into two groups;
- 457 mV for the 5-nitroimidazole, ni-
morazole, and the N-2 sulphonylimidazole,
Ro 11-5481, and -346 to -389mV for
the other compounds, as for many other
2-nitroimidazoles. There was a wide range
of water solubility, with this factor
strongly limiting the dose of Ro 12-5272.
Similarly, a wide range of lipophilicities
was tested, Ro 03-8799 being very lipo-
philic and Ro 05-9963 and Ro 12-5272
very lipophobic. The partition coefficients
in Table I are for partition between octanol
and water, although octanol may not be
the ideal model for animal fats. Since
Ro 03-8799 and Ro 03-8800 are ionized
at physiological pH (95 and 2% respec-
tively) the distribution coefficients, also
shown in Table I, might be of more rele-
vance than simple partition between
octanol and water.
The pharmacological studies, showing
peak blood levels at 10-20 min, indicate
that all the compounds tested were rapidly
absorbed into the blood stream after
i.p. injection in solution. Several drugs
reached concentrations in bloodthat would
approximate to the predicted levels,
assuming uniform distribution throughout
the body (Fig. 3). Ro 03-8799, however,
gave much lower concentrations in blood
than would be expected on the basis of
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TABLE II.-Radiobiological and pharmacological data
Administered Blood concentration Half-life
Compound dose (mg/g) at 15 min (jig/ml) SER (min)
Misonidazole 0 -02 15 1* la 40b
0 05 40 1-2a
0-1 98 1-4a
0-2 187 1-6a
0-3 323 1-75
0-4 455 2-0
0-4 423 1.9a
1.0 1127 1-95
1-0 2-2
Ro 05-9963 0-05 96 1-2 28
0-1 307 1-45
0-4 992 1-75
0.5 - 1-85
1-5 4170 2-2
Ro 03-8799 0-01 2 1 1 21
0-05 11 1-35
0-1 28 1-4
0-4 431 1-95
0-5 265 1-8
0-75 422 2-15
Ro 03-8800 0-01 10 1-50 27
0-05 60 1-15
0-1 78 1-4
0-4 722 1-7
0-5 689 1-6
1-5 6889 1 - 85
Ro 12-5272 0-05 118 1-35 60
0-1 188 1-5
0-4 603 1-9
Ro 11-5481
Nimorazole
0-4
2-5
0-4
1 -0
0-95
1-1
1-35
1-5
N.A.
N.A.
LD50 (mg/g)C
(LD1o-LD9o)
2-0
(1-9-2-2)
3 -8
(3.5-4 3)
1-8
(1.5-2-0)
3 9
(3 5-4-3)
> 8 (Oral)4
> 5 (Oral)d
1-4
(1-3-1-6)
a Values from earlier experiments (Denekamp et al., 1974), are included for comparison.
b T1/2 for MISO is known to vary from 30 to 120 min depending upon the dose administered. T1/2 deter-
mined after 0-4 mg/g in female mice except for Ro 12-5272 (0- 1 mg/g in male mice).
c LD50 values for 25-30g female WHT mice. The LD50 values for MISO can vary by a factor of 2 with
weight and strain (Denekamp et al. in prep.).
d Data for MFL mice from Dr T. R. Marten, Roche Products Ltd (personal communication).
simple distribution. These low values may
result from rapid removal by liver meta-
bolism, or by distribution into tissues with
high lipid content, or a combination of
both. Forthe following analyses it has been
assumed that the skin concentrations are
the same as blood concentrations, since
drug levels in the thin basal layer of the
mouse epidermis cannot be measured.
Table II shows that the SER for each
compound increases with increasing dose.
In Fig. 4 the SER values have been plotted
as a function of the administered dose
(A), and as a function of the blood con-
centration at irradiation (B). Smooth
curves can be fitted to each set of data,
some sensitization being observed at all
drug concentrations, even after the very
low dose of 0-01 mg/g (except with Ro
1]1-5481). When SER is plotted against
the administered dose the compounds
lie close together (Fig. 4a). None of them
appears to be much better than MISO
(triangles), but the data for Ro 03-8799
and Ro 12-5272 indicate that these com-
pounds are slightly more effective, partic-
ularly at low doses. Since there is a differ-
ence in the blood concentrations for a
given dose, and a 1-6-fold difference in
mol. wts, the curves appear more spread
out in Fig. 4(B). When SER is plotted
against molar drug concentration in blood,
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FIG. 3.-The concentration of drug, meas-
ured in blood 15 + 5 min after administra-
tion, as a function ofthe dose administered
to WHT females. The dashed line indicates
the expected concentration if the distri-
bution was uniform. Ro 05-9963 and Ro
12-5272 lie significantly above it at all doses
and Ro 03-8799 lies significantly below
(errors represent + 1 s.e.).
Ro 03-8799 is significantly more efficient
as a radiosensitizer than MISO, especially
at low concentrations, which are of most
clinical relevance.
The results for 4 ofthe compounds have
been replotted in Fig. 5, together with the
in vitro data from Adams et al. (1976),
Smithen et al. (1980) and Watts et al.
(1980) for V79 hamster cells. These in
vitro data indicated that the 2 ionized
compounds were 2-3 times more efficient
than their electron affinity suggested.
The in vivo results for MISO fall very
close to the in vitro line, if the concen-
tration at the epidermal cells is assumed
to be the same as in blood, as reported
previously (Denekamp, 1979). However,
the invivo dataforalltheother compounds
fall significantly below the in vitro line,
showing that these compounds are less
effective in vivo than would. have been
predicted on the-basis-of V79 cells. If we
001 . t1 :. 1o.
DRUG CONCENTRATION AN BLOOD" (mM)
FIG. 4.-SERs measured from pairs of clone-
survivalcurves, plotted as a function of the
administered dose (A) or themeasured drug
concentration in blood (B). (Bars represent
+s.e.) (a) There is little difference between
all the compounds when compared on the
basis of administered dose. Ro 12-5272
appears to be the most efficient, by a small
margin. (B) Ro 03-8799appears to be much
more efficient than MISO at all concen-
trations; Ro 05-9963 appears to be much
less effective.
assume a uniform distribution ofthe drugs
through all tissues, including the naturally
occurring hypoxic cells in tumours, it
seems reasonable to expect that SER
values for the hypoxic tumour cells will
be closer to the in vivo skin values than
to the in vitro values. These differences
for SER values from in vitro and in vivo
experiments contrast with the conclusion
for MISO sensitization in 4 types ofmouse
tumour, where in vitro data and in vivo
tumour results were in close agreement
(McNally et al., 1978). They do however
agree with the results of Williams et al.
(unpublished) who have seen a similar
reduction in drug efficiency when com-
paring in vivo tumour results with in
vitro data for several new compounds,
including Ro 03-8799.
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FIG. 5.-The SER values obtained for skin
clones in vivo (dotted line, and symbols) are
compared with those for V79 cells in vitro
(solid line) at equal drug concentrations.
The in vitro data are from M. E. Watts
(Smithen et al., 1980; Adams et al., 1976).
The in vivo data for MISO fall exactly on
the in vitro line. The in vivo data for the
other 3 compounds show that they are on
average 3-5 times less efficient in mouse
skin than in V79 cells in culture.
It is obvious from Figs 4 & 5 that a
comparison of different radiosensitizers
is not straightforward. The conclusions
reached will depend upon the method
chosen for comparison. In Table III the
compounds have been ranked for their
efficiency in several ways. In the first 2
columns they have been compared at
equal levels of administered dose. SERs
observed for each compound are indicated
in brackets. For the low dose of 0 1 mg/g
all 4 compounds tested gave similar SER
(1.4-1.5) and there was no significant
difference between them; they all ranked
equal. At 0 4 mg/g 3 of the compounds
(MISO, Ro 03-8799 and Ro 12-5272)
appear better than the other. Nimorazole
is clearly less effective than the 2-nitro-
imidazoles, but is slightly better than
metronidazole (Denekamp et al., 1974);
Ro 11-5481 does not sensitize at all.
The third column shows an intercompari-
son at equimolar blood concentrations
(0-1 mM), and, as in Fig. 4(B), Ro 03-8799
then seems much better than MISO.
In the fourth column sensitizers are com-
pared at doses about half the acute LD50.
Ro 12-5272 could not be administered at
such a high dose because of its low solu-
bility, so it is not listed. Ro 05-9963,
Ro 03-8799 and MISO are now ranked
equal.
A more appropriate method of ranking
might be in terms of a therapeutic index,
the ratio between a toxic and an effective
dose, i.e. what might be considered the
safety margin. Although peripheral
TABLE III.-Ranking order of the radiosensitizers
SER at various doses
il
0 4 mg/g
MISO
(1-95)
Ro 03-8799
1 -95
Ro l2-5272a
1-9
Ro 05-9963
(1-75)
Ro 03-8800
(1-7)
Nimorazole
(1-35)
Ro 11-5481
(0 95)
]Blood conc.
=01ImM
Ro 03-8799
(1.4)
Ro 03-8800
(1.2)
MISO
(1 1)
Half LD50
FRo 05-9963
(2-2)
Ro 03-8799
(2.15)
MISO
L (2-1)
Ro 03-8800
(1 -85)
Nimorazole
(1-4)
Therapeutic ratio
In viVob in vitroc
Ro 12-5272 Ro 03-8799
(80) (5.0)
Ro 05-9963 Ro 03-8800
(25) (3 - 7)
rRo 03-8800 Nimorazole
(16) (3.3)
tRo 03-8799 Ro 12-5272
(15) (2-4)
MISO MISO (14) (1-3)
Ro 05-9963
(1-3)
a The dose received was lower than 0*4 mg/g because the drug came out of solution in the syringe.
b Ratio of LD50 to the administered dose to give SER = 1 * 5.
c Ratio of concentration to give 50% cell kill on exposure for 7-14 days under aerobic conditions to the
dose giving SER=1 6. Data from Adams et al. (1979b), Smithen et al. (1980), Watts et al. (1980).
0-1 mg/g
Ro 12-5272
(1-5)
Ro 05-9963
(1 -45)
MISO
(1-4)
Ro 03-8799
(1-4)
Ro 03-8800
(1-4)
Rank
I
2
3
4
5
6
7
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neuropathy is the clinical complication of
most concern, there are no proven relevant
tests for this in small rodents. Acute
lethality is the only toxic endpoint that
we have studied, so the LD50 has been
taken as a measure of toxicity and com-
pared with the dose that would give an
SER of 1'5, i.e. - 30% of the full sensiti-
zation with 2. The ratio of these two is
indicated in brackets. Since the insoluble
Ro 12-5272 is extremely non-toxic, pos-
sibly because it had to be administered
orally for the lethality tests, it ranks much
higher than any other drug. Ro 03-8799,
Ro 03-8800 and MISO are similar on this
"therapeutic index" comparison, and Ro
05-9963 is somewhat more effective.
The final column shows the therapeutic
index assessed in vitro, in a similar manner,
by comparing aerobic cytotoxicity with
radiosensitizing efficiency. The compounds
do not rank in a similar sequence; in
particular nimorazole is ranked much
higher than in vivo. The reason for this
difference in ranking orders between in
vitro and in vivo is not understood, but
both measures of toxicity (i.e. in mice
and in dishes) are arbitrary and may have
no clinical significance. The variations in
therapeutic ratio in vitro are not very
large (by a factor of 4) whereas the factors
in vivo are greater (8: 1) being mainly
influenced, however, by the lethality
test for toxicity. Ro 12-5272 may be
relatively non-toxic after oral admini-
stration because of poor absorption from
the intestine. Other tests (e.g. of neuro-
toxicity) are urgently needed for all these
radiosensitizers before making a more
clinically useful comparison.
Several nitroimidazoles have been
ranked for their neurotoxicity, as assessed
experimentally in rodents, but a poor
correlation with clinical results has re-
cently been demonstrated with the Phase
I studies ofdesmethyl MISO (Ro 05-9963).
This compound appeared to be 2-3 times
less toxic in mice than MISO (e.g. Clarke
et al., 1980) but in man it gives
qualitatively and quantitatively similar
peripheral neuropathy, and is limited
to the same total dose of - 12 g/m2
(Dische et al., 1981). This inability to
predict toxicity in mice may result from
the gross differences in pharmacokinetics,
or because the clinical symptoms are
reflecting sensory defects whereas the
rodent tests are mainly for motor function.
Until this problem is solved no adequate
animal model for toxicity is available and
this will hinder the ranking of potential
successors to misonidazole.
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